466 related articles for article (PubMed ID: 12078084)
1. [Therapy for children with Shiga toxin-E. coli-associated hemolytic uremic syndrome].
Ito K; Hattori M; Matsumoto N
Nihon Rinsho; 2002 Jun; 60(6):1126-30. PubMed ID: 12078084
[TBL] [Abstract][Full Text] [Related]
2. Pathophysiology and management of thrombotic microangiopathies.
Ruggenenti P; Remuzzi G
J Nephrol; 1998; 11(6):300-10. PubMed ID: 10048496
[TBL] [Abstract][Full Text] [Related]
3. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion.
Ake JA; Jelacic S; Ciol MA; Watkins SL; Murray KF; Christie DL; Klein EJ; Tarr PI
Pediatrics; 2005 Jun; 115(6):e673-80. PubMed ID: 15930195
[TBL] [Abstract][Full Text] [Related]
4. Thrombotic microangiopathies: thrombotic thrombocytopenic purpura / hemolytic uremic syndrome.
Polito MG; Kirsztajn GM
J Bras Nefrol; 2010; 32(3):303-15. PubMed ID: 21103695
[TBL] [Abstract][Full Text] [Related]
5. Prevalence, virulence profiles, and clinical significance of Shiga toxin-negative variants of enterohemorrhagic Escherichia coli O157 infection in humans.
Friedrich AW; Zhang W; Bielaszewska M; Mellmann A; Köck R; Fruth A; Tschäpe H; Karch H
Clin Infect Dis; 2007 Jul; 45(1):39-45. PubMed ID: 17554698
[TBL] [Abstract][Full Text] [Related]
6. Hemolytic-uremic syndrome associated with an infection by verotoxin producing Escherichia coli 0111 in a woman on oral contraceptives.
Stenger KO; Windler F; Karch H; von Wulffen H; Heesemann J
Clin Nephrol; 1988 Mar; 29(3):153-8. PubMed ID: 3282732
[TBL] [Abstract][Full Text] [Related]
7. [Hemolytic uremic syndrome].
Rota S; Cravedi P; Remuzzi G; Ruggenenti P
G Ital Nefrol; 2005; 22 Suppl 33():S57-64. PubMed ID: 16419008
[TBL] [Abstract][Full Text] [Related]
8. Treatment of typical (enteropathic) hemolytic uremic syndrome.
Bitzan M; Schaefer F; Reymond D
Semin Thromb Hemost; 2010 Sep; 36(6):594-610. PubMed ID: 20865636
[TBL] [Abstract][Full Text] [Related]
9. [Hemolytic uremic syndrome caused by enterohaemorrhagic Escherichia coli].
Ibarra C; Goldstein J; Silberstein C; Zotta E; Belardo M; Repetto HA
Arch Argent Pediatr; 2008 Oct; 106(5):435-42. PubMed ID: 19030644
[TBL] [Abstract][Full Text] [Related]
10. Association between hemolytic uremic syndrome and verotoxin-producing strains of E. coli.
Jure MA; de Saab OA; de Castillo MC; Sesma F; Miceli S; Zamora AM; de Ruiz Holgado AP; de Nader OM
Rev Latinoam Microbiol; 1998; 40(1-2):1-8. PubMed ID: 10932728
[TBL] [Abstract][Full Text] [Related]
11. Cluster of hemolytic-uremic syndrome caused by Shiga toxin-producing Escherichia coli O26:H11.
Misselwitz J; Karch H; Bielazewska M; John U; Ringelmann F; Rönnefarth G; Patzer L
Pediatr Infect Dis J; 2003 Apr; 22(4):349-54. PubMed ID: 12690276
[TBL] [Abstract][Full Text] [Related]
12. [Hemolytic uremic syndrome in children of Mendoza, Argentina: association with Shiga toxin-producing Escherichia coli infection].
Rivas M; Balbi L; Miliwebsky ES; García B; Tous MI; Leardini NA; Prieto MA; Chillemi GM; de Principi ME
Medicina (B Aires); 1998; 58(1):1-7. PubMed ID: 9674201
[TBL] [Abstract][Full Text] [Related]
13. Hemolytic uremic syndrome associated with Escherichia coli O157:H7 infection in older adults: a case report and review of the literature.
Ko H; Maymani H; Rojas-Hernandez C
J Med Case Rep; 2016 Jun; 10():175. PubMed ID: 27301547
[TBL] [Abstract][Full Text] [Related]
14. Hemolytic uremic syndrome and death in persons with Escherichia coli O157:H7 infection, foodborne diseases active surveillance network sites, 2000-2006.
Gould LH; Demma L; Jones TF; Hurd S; Vugia DJ; Smith K; Shiferaw B; Segler S; Palmer A; Zansky S; Griffin PM
Clin Infect Dis; 2009 Nov; 49(10):1480-5. PubMed ID: 19827953
[TBL] [Abstract][Full Text] [Related]
15. [Microangiopathic hemolytic anemias. Clinical pattern, therapy and clinical course in 14 patients with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome].
Krause M; Fehr J; Gmür J; Keusch G; Frick P; Oelz O
Schweiz Med Wochenschr; 1986 Nov; 116(48):1666-74. PubMed ID: 3798063
[TBL] [Abstract][Full Text] [Related]
16. Thrombotic microangiopathy: current knowledge and outcomes with plasma exchange.
Clark WF
Semin Dial; 2012; 25(2):214-9. PubMed ID: 22309967
[TBL] [Abstract][Full Text] [Related]
17. Clinical features of critically ill patients with Shiga toxin-induced hemolytic uremic syndrome.
Braune SA; Wichmann D; von Heinz MC; Nierhaus A; Becker H; Meyer TN; Meyer GP; Müller-Schulz M; Fricke J; de Weerth A; Hoepker WW; Fiehler J; Magnus T; Gerloff C; Panzer U; Stahl RA; Wegscheider K; Kluge S
Crit Care Med; 2013 Jul; 41(7):1702-10. PubMed ID: 23660733
[TBL] [Abstract][Full Text] [Related]
18. Hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli 0111.
Azadi R; Calabrese K; Stroup J
J Am Osteopath Assoc; 2010 Sep; 110(9):538-44. PubMed ID: 20876839
[TBL] [Abstract][Full Text] [Related]
19. Hemolytic uremic syndrome: an emerging health risk.
Razzaq S
Am Fam Physician; 2006 Sep; 74(6):991-6. PubMed ID: 17002034
[TBL] [Abstract][Full Text] [Related]
20. Escherichia coli O157:H7 infections: discordance between filterable fecal shiga toxin and disease outcome.
Cornick NA; Jelacic S; Ciol MA; Tarr PI
J Infect Dis; 2002 Jul; 186(1):57-63. PubMed ID: 12089662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
